Luciano Ferreira Drager, Márcia Assis, Andrea Frota Rego Bacelar, Dalva Lucia Rollemberg Poyares, Silvia Gonçalves Conway, Gabriel Natan Pires, Alexandre Pinto de Azevedo, Alicia Carissimi, Allan Luiz Eckeli, Álvaro Pentagna, Carlos Maurício Oliveira Almeida, Clélia Maria Ribeiro Franco, Emmanuelle Silva Tavares Sobreira, Fernando Gustavo Stelzer, Giuliana Macedo Mendes, Gisele Richter Minhoto, Ila Marques Porto Linares, Ksdy Maiara Moura Sousa, Livia Leite Góes Gitaí, Lucia Sukys-Claudino, Manoel Alves Sobreira-Neto, Marcio Andrei Zanini, Regina Margis & Sandra Cristina Gonçalves Martinez. (2023) 2023 Guidelines on the Diagnosis and Treatment of Insomnia in Adults – Brazilian Sleep Association. Sleep Science 16:S 02.
Crossref
Sifan Hu, Le Shi, Zhe Li, Yundong Ma, Jinyu Li, Yanping Bao, Lin Lu & Hongqiang Sun. (2023) First‐night effect in insomnia disorder: a systematic review and meta‐analysis of polysomnographic findings. Journal of Sleep Research.
Crossref
Bei Pan, Long Ge, Honghao Lai, Liangying Hou, Chen Tian, Qi Wang, Kelu Yang, Yao Lu, Hongfei Zhu, Mengting Li, Deren Wang, Xiuxia Li, Yuqing Zhang, Ya Gao, Ming Liu, Guowu Ding, Jinhui Tian & Kehu Yang. (2023) The Comparative Effectiveness and Safety of Insomnia Drugs: A Systematic Review and Network Meta-Analysis of 153 Randomized Trials. Drugs 83:7, pages 587-619.
Crossref
Nathaniel F. Watson, Ruth M. Benca, Andrew D. Krystal, William V. McCall & David N. Neubauer. (2023) Alliance for Sleep Clinical Practice Guideline on Switching or Deprescribing Hypnotic Medications for Insomnia. Journal of Clinical Medicine 12:7, pages 2493.
Crossref
Aitana Calvo, Mercedes González-Hidalgo, Ana Terleira, Nieves Fernández & Antonio Portolés. (2022) Carisoprodol Single and Multiple Dose PK-PD. Part II: Pharmacodynamics Evaluation Method for Central Muscle Relaxants. Double-Blind Placebo-Controlled Clinical Trial in Healthy Volunteers. Journal of Clinical Medicine 11:4, pages 1141.
Crossref
Heather McElroyBeth O’LearyMichael AdenaRenee CampbellAmir Abbas Tahami MonfaredGenevieve Meier. (2021) Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis. Journal of Managed Care & Specialty Pharmacy 27:9, pages 1296-1308.
Crossref
Nathaniel F. Watson, Catherine McCall & Michael Doherty. (2021) Faradization for insomnia: a sleep neurology history. Journal of Clinical Sleep Medicine 17:2, pages 249-254.
Crossref
Steven P. Stanos, Mark D. Tyburski,R. Norman Harden. 2021. Braddom's Physical Medicine and Rehabilitation. Braddom's Physical Medicine and Rehabilitation
748
773.e5
.
Stephen M. Stahl. 2021. Prescriber's Guide. Prescriber's Guide
285
288
.
Stephen M. Stahl. 2021. Prescriber's Guide. Prescriber's Guide.
Alain Nicolas & Perrine M. Ruby. (2020) Dreams, Sleep, and Psychotropic Drugs. Frontiers in Neurology 11.
Crossref
Binghu Jiang, Dongmei He, Zhiwei Guo & Zhanhui Gao. (2020) Dynamic features of placebo effects addressing persistent insomnia disorder: A meta‐analysis of placebo‐controlled randomized clinical trials. Journal of Sleep Research 29:4.
Crossref
Dongmei He, Binghu Jiang, Zhiwei Guo, Qiwen Mu & Morgan A Mcclure. (2020) Biphasic feature of placebo response in primary insomnia: pooled analysis of data from randomized controlled clinical trials of orexin receptor antagonists. Sleep 43:3.
Crossref
Marek Jarema & Adam Wichniak. (2020) Eszopiclone in the treatment of insomnia. Pharmacotherapy in Psychiatry and Neurology 36:1, pages 9-21.
Crossref
Binghu Jiang, Dongmei He & Zhanhui Gao. (2019) Efficacy and Placebo Response of Multimodal Treatments for Primary Insomnia: A Network Meta-Analysis. Clinical Neuropharmacology 42:6, pages 197-202.
Crossref
Laura J. Mitchell, Lampros Bisdounis, Andrea Ballesio, Ximena Omlin & Simon D. Kyle. (2019) The impact of cognitive behavioural therapy for insomnia on objective sleep parameters: A meta-analysis and systematic review. Sleep Medicine Reviews 47, pages 90-102.
Crossref
Liang Liang, Yabing Huang, Rong Xu, Yanyan Wei, Ling Xiao & Gaohua Wang. (2019) Eszopiclone for the treatment of primary insomnia: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials. Sleep Medicine 62, pages 6-13.
Crossref
Andrew D. Krystal, Aric A. Prather & Liza H. Ashbrook. (2019) The assessment and management of insomnia: an update. World Psychiatry 18:3, pages 337-352.
Crossref
Susanne Rösner, Christian Englbrecht, Renate Wehrle, Göran Hajak & Michael Soyka. (2018) Eszopiclone for insomnia. Cochrane Database of Systematic Reviews 2018:10.
Crossref
Yung-Tsan Wu. 2018. Braddom's Rehabilitation Care: A Clinical Handbook. Braddom's Rehabilitation Care: A Clinical Handbook
257
263.e9
.
William Maurice Redden. 2018. Clinical Psychopharmacology for Neurologists. Clinical Psychopharmacology for Neurologists
97
115
.
Jaime M. Monti. 2017. Sleep Disorders Medicine. Sleep Disorders Medicine
1187
1207
.
A Villa, A Wolff, N Narayana, C Dawes, DJ Aframian, AM Lynge Pedersen, A Vissink, A Aliko, YW Sia, RK Joshi, R McGowan, SB Jensen, AR Kerr, J Ekström & G Proctor. (2016) World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction. Oral Diseases 22:5, pages 365-382.
Crossref
Daniel F. Kripke. (2018) Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit. F1000Research 5, pages 918.
Crossref
Daniel F. Kripke. (2017) Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit. F1000Research 5, pages 918.
Crossref
Daniel F. Kripke. (2016) Hypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit. F1000Research 5, pages 918.
Crossref
Neely Ivgy-May, Frank Ruwe, Andrew Krystal & Thomas Roth. (2015) Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a randomized, 6-week sleep laboratory trial. Sleep Medicine 16:7, pages 838-844.
Crossref
Philip M. Becker & Manya Somiah. (2015) Non–Benzodiazepine Receptor Agonists for Insomnia. Sleep Medicine Clinics 10:1, pages 57-76.
Crossref
Jadwiga S. Najib. 2015. Drug Treatment of Sleep Disorders. Drug Treatment of Sleep Disorders
159
189
.
Harold W. Goforth, Xavier A. Preud'homme & Andrew D. Krystal. (2014) A Randomized, Double-Blind, Placebo-Controlled Trial of Eszopiclone for the Treatment of Insomnia in Patients with Chronic Low Back Pain. Sleep 37:6, pages 1053-1060.
Crossref
Erin J. Wamsley, Ann K. Shinn, Matthew A. Tucker, Kim E. Ono, Sophia K. McKinley, Alice V. Ely, Donald C. Goff, Robert Stickgold & Dara S. Manoach. (2013) The Effects of Eszopiclone on Sleep Spindles and Memory Consolidation in Schizophrenia: A Randomized Placebo-Controlled Trial. Sleep 36:9, pages 1369-1376.
Crossref
Naren Gunja. (2013) In the Zzz Zone: The Effects of Z-Drugs on Human Performance and Driving. Journal of Medical Toxicology 9:2, pages 163-171.
Crossref
Peter Bytzer, Stephen Pratt, Eric Elkin, Jørgen Næsdal & Elisabeth Sörstadius. (2012) Burden of Upper Gastrointestinal Symptoms in Patients Receiving Low-Dose Acetylsalicylic Acid for Cardiovascular Risk Management. American Journal of Cardiovascular Drugs 13:1, pages 27-35.
Crossref
Naohisa Uchimura, Atsushi Kamijo, Hiroo Kuwahara, Makoto Uchiyama, Tetsuo Shimizu, Shigeru Chiba & Yuichi Inoue. (2012) A randomized placebo-controlled polysomnographic study of eszopiclone in Japanese patients with primary insomnia. Sleep Medicine 13:10, pages 1247-1253.
Crossref
Catherine McCall & W. Vaughn McCall. (2012) What Is the Role of Sedating Antidepressants, Antipsychotics, and Anticonvulsants in the Management of Insomnia?. Current Psychiatry Reports 14:5, pages 494-502.
Crossref
P Hoever, G Dorffner, H Beneš, T Penzel, H Danker-Hopfe, M J Barbanoj, G Pillar, B Saletu, O Polo, D Kunz, J Zeitlhofer, S Berg, M Partinen, C L Bassetti, B Högl, I O Ebrahim, E Holsboer-Trachsler, H Bengtsson, Y Peker, U-M Hemmeter, E Chiossi, G Hajak & J Dingemanse. (2012) Orexin Receptor Antagonism, a New Sleep-Enabling Paradigm: A Proof-of-Concept Clinical Trial. Clinical Pharmacology & Therapeutics 91:6, pages 975-985.
Crossref
Daniel P. Cardinali, Venkataramanujan Srinivasan, Amnon Brzezinski & Gregory M. Brown. (2012) Melatonin and its analogs in insomnia and depression. Journal of Pineal Research 52:4, pages 365-375.
Crossref
Naohisa Uchimura, Atsushi Kamijo & Takao Takase. (2012) Effects of eszopiclone on safety, subjective measures of efficacy, and quality of life in elderly and nonelderly Japanese patients with chronic insomnia, both with and without comorbid psychiatric disorders: a 24-week, randomized, double-blind study. Annals of General Psychiatry 11:1, pages 15.
Crossref
Susmita Chowdhuri. 2012. Essentials of Sleep Medicine. Essentials of Sleep Medicine
17
54
.
Robert N. Pechnick, Liliana M. Lacayo, Charlene M. Manalo, Yasmin Bholat & Inna Spivak. (2011) Eszopiclone stimulates the hypothalamo-pituitary-adrenal axis in the rat. European Journal of Pharmacology 661:1-3, pages 22-26.
Crossref
Venkatramanujan Srinivasan, Amnon Brzezinski, Seithikurippu R. Pandi-Perumal, D. Warren Spence, Daniel P. Cardinali & Gregory M. Brown. (2011) Melatonin agonists in primary insomnia and depression-associated insomnia: Are they superior to sedative-hypnotics?. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35:4, pages 913-923.
Crossref
Janine M. Hall-Porter, D. Troy Curry & James K. Walsh. (2010) Pharmacologic Treatment of Primary Insomnia. Sleep Medicine Clinics 5:4, pages 609-625.
Crossref
David J NuttS M Stahl. (2009)
Searching for perfect sleep: the continuing evolution of GABA
A
receptor modulators as hypnotics
. Journal of Psychopharmacology 24:11, pages 1601-1612.
Crossref
David J NuttCelia L Feetam. (2010) What one hand giveth the other taketh away: some unpredicted effects of enantiomers in psychopharmacology. Journal of Psychopharmacology 24:8, pages 1137-1141.
Crossref
Max P. Huang, Kushan Radadia, Brian W. Macone, Sanford H. Auerbach & Subimal Datta. (2010) Effects of eszopiclone and zolpidem on sleep–wake behavior, anxiety-like behavior and contextual memory in rats. Behavioural Brain Research 210:1, pages 54-66.
Crossref
Taeko Sasai, Yuichi Inoue, Yoko Komada, Takashi Nomura, Masato Matsuura & Eisuke Matsushima. (2010) Effects of insomnia and sleep medication on health-related quality of life. Sleep Medicine 11:5, pages 452-457.
Crossref
Gary K Zammit. 2010. Insomnia. Insomnia
436
452
.
Vaughn W McCall. 2010. Insomnia. Insomnia
397
409
.
Andrew D Krystal. 2010. Insomnia. Insomnia
375
386
.
Hadine Joffe, Laura Petrillo, Adele Viguera, Alexia Koukopoulos, Kate Silver-Heilman, Adriann Farrell, Gary Yu, Michael Silver & Lee S. Cohen. (2010) Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial. American Journal of Obstetrics and Gynecology 202:2, pages 171.e1-171.e11.
Crossref
Hussien A. Al-Shamma, Christen Anderson, Emil Chuang, Remy Luthringer, Andrew J. Grottick, Erin Hauser, Michael Morgan, William Shanahan, Bradley R. Teegarden, William J. Thomsen & Dominic Behan. (2010)
Nelotanserin, a Novel Selective Human 5-Hydroxytryptamine
2A
Inverse Agonist for the Treatment of Insomnia
. Journal of Pharmacology and Experimental Therapeutics 332:1, pages 281-290.
Crossref
Jadwiga S. Najib. 2010. GABA and Sleep. GABA and Sleep
413
451
.
Jaime M. Monti & Daniel Monti. 2010. Principles and Practice of Geriatric Sleep Medicine. Principles and Practice of Geriatric Sleep Medicine
344
361
.
Gary Zammit. (2009) Comparative Tolerability of Newer Agents for Insomnia. Drug Safety 32:9, pages 735-748.
Crossref
Andrew D. Krystal. (2009) A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: The empirical basis for U.S. clinical practice. Sleep Medicine Reviews 13:4, pages 265-274.
Crossref
Anna K. Morin & Kristine Willett. (2009) The role of eszopiclone in the treatment of insomnia. Advances in Therapy 26:5, pages 500-518.
Crossref
Natalie D. Dautovich, Jacob M. Williams & Christina S. McCrae. (2009) Insomnia: A Review of the Use of Eszopiclone. Clinical Medicine. Therapeutics 1, pages CMT.S1940.
Crossref
Wallace B. Mendelson. (2008) Pharmacologic Treatment of Insomnia. Psychiatric Annals 38:9.
Crossref
Julia Boyle, Leanne Trick, Sigurd Johnsen, James Roach & Robert Rubens. (2008) Next‐day cognition, psychomotor function, and driving‐related skills following nighttime administration of eszopiclone. Human Psychopharmacology: Clinical and Experimental 23:5, pages 385-397.
Crossref
Syed H. Tariq & Shailaja Pulisetty. (2008) Pharmacotherapy for Insomnia. Clinics in Geriatric Medicine 24:1, pages 93-105.
Crossref
Philip I Hair, Paul L McCormack & Monique P Curran. (2008) Spotlight on Eszopiclone in Insomnia†. CNS Drugs 22:11, pages 975-978.
Crossref
Chris Alford & Sue Wilson. 2008. Sleep and Quality of Life in Clinical Medicine. Sleep and Quality of Life in Clinical Medicine
53
66
.
Mathias B. Forrester. (2016) Eszopiclone ingestions reported to Texas poison control centers, 2005—2006. Human & Experimental Toxicology 26:10, pages 795-800.
Crossref
Russell Rosenberg, James M. Roach, Martin Scharf & David A. Amato. (2007) A pilot study evaluating acute use of eszopiclone in patients with mild to moderate obstructive sleep apnea syndrome. Sleep Medicine 8:5, pages 464-470.
Crossref
Gary K Zammit. (2007) Eszopiclone: a nonbenzodiazepine that effectively improves sleep maintenance and initiation in patients with insomnia. Future Neurology 2:3, pages 249-257.
Crossref
Keith A. Wafford & Paul J. Whiting. 2007. Handbook of Contemporary Neuropharmacology. Handbook of Contemporary Neuropharmacology.
L.M. McDonald, W.F. Sheppard, S.M. Staveley, B. Sohal, F.D. Tattersall & P.H. Hutson. (2007) Gaboxadol, a selective extrasynaptic GABAA agonist, does not generalise to other sleep-enhancing drugs: A rat drug discrimination study. Neuropharmacology 52:3, pages 844-853.
Crossref
Anna K. Morin, Courtney I. Jarvis & Ann M. Lynch. (2012) Therapeutic Options for Sleep‐Maintenance and Sleep‐Onset Insomnia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 27:1, pages 89-110.
Crossref
James R. Taylor, Cristina M. Vazquez & Kendall M. Campbell. (2006) Pharmacologic Management of Chronic Insomnia. Southern Medical Journal 99:12, pages 1373-1377.
Crossref
Andrew D. Krystal, Shari Rogers & Margaret A. Fitzgerald. (2006) Long-Term Pharmacotherapy in the Management of Chronic Insomnia. The Journal for Nurse Practitioners 2:9, pages S621-S632.
Crossref
Maurizio Fava, W. Vaughn McCall, Andrew Krystal, Thomas Wessel, Robert Rubens, Judy Caron, David Amato & Thomas Roth. (2006) Eszopiclone Co-Administered With Fluoxetine in Patients With Insomnia Coexisting With Major Depressive Disorder. Biological Psychiatry 59:11, pages 1052-1060.
Crossref
Jadwiga Najib. (2006) Eszopiclone, a Nonbenzodiazepine Sedative-Hypnotic Agent for the Treatment of Transient and Chronic Insomnia. Clinical Therapeutics 28:4, pages 491-516.
Crossref
Cynthia J. Halas. (2006) Eszopiclone. American Journal of Health-System Pharmacy 63:1, pages 41-48.
Crossref
Russell P. Rosenberg. (2006) Sleep Maintenance Insomnia: Strengths and Weaknesses of Current Pharmacologic Therapies. Annals of Clinical Psychiatry 18:1, pages 49-56.
Crossref
Jaime M. Monti & Daniel Monti. 2006. Clinical Pharmacology of Sleep. Clinical Pharmacology of Sleep
207
223
.
C. N. Soares. (2005) Insomnia in women: an overlooked epidemic?. Archives of Women's Mental Health 8:4, pages 205-213.
Crossref
Sarah T Melton, Jill M Wood & Cynthia K Kirkwood. (2005) Eszopiclone for Insomnia. Annals of Pharmacotherapy 39:10, pages 1659-1666.
Crossref
. (2005) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 14:8, pages i-xii.
Crossref
Dalva Poyares, Luciano Ribeiro Pinto Jr, Stella Tavares & Sergio Barros-Vieira. (2005) Hipnoindutores e insônia. Revista Brasileira de Psiquiatria 27:suppl 1, pages 2-7.
Crossref
Dennis J. CadaTerri LevienDanial E. Baker. (2017) Eszopiclone. Hospital Pharmacy 40:5, pages 430-442.
Crossref